Regulus Therapeutics (RGLS) Reports In-Line Q1 EPS

Regulus Therapeutics (NASDAQ: RGLS) reported Q1 EPS of ($0.15), in-line with the analyst estimate of ($0.15).

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• CVG to join Russell 2000 and Russell 3000 indexes June 26
• St. James's Place plc (STJ:LN) (STJPF) PT Raised to GBP20.50 at Deutsche Bank